[go: up one dir, main page]

WO2018014100A1 - Forme de présentation de chlorure de magnésium comestible - Google Patents

Forme de présentation de chlorure de magnésium comestible Download PDF

Info

Publication number
WO2018014100A1
WO2018014100A1 PCT/BR2017/050193 BR2017050193W WO2018014100A1 WO 2018014100 A1 WO2018014100 A1 WO 2018014100A1 BR 2017050193 W BR2017050193 W BR 2017050193W WO 2018014100 A1 WO2018014100 A1 WO 2018014100A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnesium chloride
oil
ingestible
presentation according
presentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2017/050193
Other languages
English (en)
Portuguese (pt)
Inventor
Luiz Francisco Pianowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018014100A1 publication Critical patent/WO2018014100A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • This invention relates to an ingestible magnesium chloride presentation, characterized in that it comprises a mixture of magnesium chloride and an oil, and said mixture is contained in a soft capsule.
  • Magnesium chloride is a compound typically used as a laxative, like other magnesium salts, however the benefits disclosed in the prior art extend to several other aspects by the administration of magnesium ions: immunostimulant, toning, blood pressure stabilizer, treatment of external injuries, etc.
  • magnesium chloride is considered to be the only one that is fully ionizable and therefore most accessible to body.
  • magnesium chloride is one of several osmotic purgatives, which act by increasing intestinal osmotic pressure by promoting fluid retention in the intestine. Its effect on intestinal motility and stool consistency or hardness is amplified with the amount ingested in a single dose.
  • magnesium chloride has some drawbacks.
  • magnesium chloride is a very hygroscopic compound. To allow its proper compression, it is necessary to use other salts, which are not as efficient as laxatives, and are less ionizable.
  • the present invention proposes the presentation of magnesium chloride as a mixture of magnesium chloride with an oil, such mixture contained in a capsule, preferably soft capsule.
  • Magnesium chloride suitable for the invention may be anhydrous or hydrated.
  • soft capsule means a single body capsule, also known as a softgel.
  • soft and hard capsules are both gelatinous, the soft capsule is more readily soluble in biological fluids at room temperature, and is best suited for the delivery of liquids such as oils, suspensions, emulsions, and semisolids, while hard capsules are retained. solids, granules or powders.
  • oils of mineral, vegetable or animal nature which may be associated with magnesium chloride in any acceptable form, for example dispersion or emulsion are used. Mixtures of these oils in any proportion are also covered by the invention.
  • vegetable oils for example, but not limited to soybean, coconut, corn, sunflower seed, cottonseed, olive, palm oil. , peanut, almond, Brazil nuts, cashews, macadamia nuts, hazelnuts, pecans, pistachios, walnuts, acai, flax, etc. and their mixtures.
  • Animal oils are also suitable for use in the invention, provided they are pharmaceutically acceptable, such as fish oil, cod liver oil, salmon, trout oil, etc., and mixtures thereof.
  • the mixture of magnesium chloride and oil according to the invention may contain excipients known to the person skilled in the art and may contain other actives, for example, without excluding any others, one or more antibiotic, hormone, antioxidant, antihypertensive, muscle relaxant, vitamin, analgesic, antihyperlipidemic, etc.
  • the soft capsule of the invention may contain dyes, and have surface impression.
  • the amount of magnesium chloride ranges from 5 to 5000 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme de présentation de chlorure de magnésium comestible, caractérisé en ce qu'elle comprend un mélange de chlorure de magnésium et une huile, ledit mélange étant contenu dans une capsule molle.
PCT/BR2017/050193 2016-07-18 2017-07-17 Forme de présentation de chlorure de magnésium comestible Ceased WO2018014100A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016016559-8A BR102016016559A2 (pt) 2016-07-18 2016-07-18 Apresentação de cloreto de magnésio ingerível
BRBR1020160165598 2016-07-18

Publications (1)

Publication Number Publication Date
WO2018014100A1 true WO2018014100A1 (fr) 2018-01-25

Family

ID=60991721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2017/050193 Ceased WO2018014100A1 (fr) 2016-07-18 2017-07-17 Forme de présentation de chlorure de magnésium comestible

Country Status (2)

Country Link
BR (1) BR102016016559A2 (fr)
WO (1) WO2018014100A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104078A1 (en) * 2001-03-30 2003-06-05 Bridget Barrett-Reis Method of improving the antioxidant status of an infant
US20050054724A1 (en) * 2003-09-05 2005-03-10 Mustad Vikkie A. Lipid system and methods of use
US8168611B1 (en) * 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US20130022673A1 (en) * 2003-08-15 2013-01-24 Russell Jaffe Enhancement of magnesium uptake in mammals
US20140271908A1 (en) * 2013-03-15 2014-09-18 Melaleuca, Inc. Dietary supplements and methods for preventing and treating migraines
US20160022594A1 (en) * 2013-03-15 2016-01-28 Russell Jaffe Soft gel encapsulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104078A1 (en) * 2001-03-30 2003-06-05 Bridget Barrett-Reis Method of improving the antioxidant status of an infant
US20130022673A1 (en) * 2003-08-15 2013-01-24 Russell Jaffe Enhancement of magnesium uptake in mammals
US20050054724A1 (en) * 2003-09-05 2005-03-10 Mustad Vikkie A. Lipid system and methods of use
US8168611B1 (en) * 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US20140271908A1 (en) * 2013-03-15 2014-09-18 Melaleuca, Inc. Dietary supplements and methods for preventing and treating migraines
US20160022594A1 (en) * 2013-03-15 2016-01-28 Russell Jaffe Soft gel encapsulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHAJEHALI, E. ET AL.: "Effects of chronic administration of calcium- magnesium soft gels on morphine tolerance and dependence in mice", MAGNESIUM RESEARCH, vol. 22, no. 2, 1 June 2009 (2009-06-01), pages 81 - 88, XP055454874 *
PICKERING, G. ET AL.: "Oral magnesium treatment in patients with neuropathic pain: a randomized clinical trial.", MAGNESIUM RESEARCH, vol. 24, no. 2, 2011, pages 28 - 35, XP055454869 *

Also Published As

Publication number Publication date
BR102016016559A2 (pt) 2018-02-06

Similar Documents

Publication Publication Date Title
US20140088047A1 (en) Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
ES2201673T3 (es) Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
BR112015015864B1 (pt) Uso de uma composição farmacêutica no tratamento de uma condição de dor severa
CN103608023A (zh) 磷虾油的胃肠外治疗应用
US20100331415A1 (en) Use of omega-3-fatty acid(s)
Cicero et al. Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability
RU2010120706A (ru) Композиция липоевой кислоты в виде шариков
US20190314406A1 (en) Transdermal magnesium cream compositions
Stemmermann et al. Strongyloides stercoralis infestation: malabsorption defect with reaction to dithiazanine iodide
JP2003088329A (ja) 鎮痛用健康補助食品
US20080153782A1 (en) Use of Lecithin as a Medication for the Treatment of Psoriasis
Lionel et al. Levamisole in the treatment of ascariasis in children
ES2208330T3 (es) Composiciones para modular la respuesta nmune y para el tratamiento de la enfermedad inflamatoria.
JP7294147B2 (ja) 侵害受容性疼痛の予防又は改善用組成物
WO2018014100A1 (fr) Forme de présentation de chlorure de magnésium comestible
US20170266130A1 (en) Compositions, methods for making the compositions, and methods for treating joint disease
TW201717929A (zh) 包括卡立胺酯之藥物及其於預防、緩解或治療疼痛或癲癎之用途
JP5279343B2 (ja) 坐薬製剤組成物
JP5296968B2 (ja) イブプロフェン含有経口用医薬組成物
JP6940264B2 (ja) 止瀉剤組成物
JP6940265B2 (ja) 止瀉剤組成物
Mitsugi et al. Protection against methotrexate toxicity by a soybean protein-and ω-3 fatty acid-containing diet: Comparative study with a casein-containing diet
PT85454B (pt) Processo para a preparacao de composicoes farmaceuticas contendo 15-deoxiespergualina
BR102016016555A2 (pt) Uso de uma fração de óleo de cravo
JP2013126971A (ja) 抗感冒剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17830128

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17830128

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 27/03/2019)